Press releases

Dassault Systèmes and Inserm Announce Joint Agreement to Decipher Disease Complexity and Accelerate Clinical Research

29 Mar 2016 | By Inserm (Newsroom) | Institutional and special event

Next Generation Scientific Innovation with the 3DEXPERIENCE Platform and Strategic Collaboration to Advance Programs in Aging, Cancer, Genomics and Microbiota

plateforme 3Dexperience

3DEXPERIENCE Plateform (c) Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, and the French National Institute of Health and Medical Research (Inserm), the only French public research institute to focus entirely on human health and the largest in Europe, today announced the signature of a joint agreement to accelerate clinical research programs by deploying a virtual collaborative platform.  The agreement will draw from the expertise of each organization to offer new perspectives for addressing scientific and health challenges of the 21st century.

Inserm will use Dassault Systèmes’ 3DEXPERIENCE platform to conduct its strategic biomedical research programs in the areas of aging, cancer, genomics and microbiota.  The platform provides Inserm with an integrated virtual environment for open collaborative research, unified laboratory management and biological and chemical modeling and simulation from Dassault Systèmes’ flagship brand dedicated to scientific excellence, BIOVIA.

In turn, Dassault Systèmes will leverage big data from Inserm’s research programs to calibrate and validate scientific models that can be applied to future technologies for the clinical research domain. These models will enable the company to develop next-generation industry solution experiences targeting clinical trials, to accelerate decision-making and to enable earlier efficacy and safety demonstration with virtual trials.

“We seek out technologies that further our mission to observe and understand mechanisms of the living body and ultimately transfer this knowledge to therapeutic solutions for new and mutating diseases that are affecting the world’s growing population,” said Professor Yves Lévy, Chairman and CEO, Inserm.

“We lead long-term, competitive scientific programs in human health and medicine and the Dassault Systèmes’ 3DEXPERIENCE platform will help us support collaboration, project management, data, resources, traceability and other processes”


“At its core, Dassault Systèmes is a scientific company.  And at its core, Inserm explores the finest elements of life as we know it—fundamental science.  Clinical research has been the catalyst for life-changing discoveries during our lifetime, and introducing capabilities such as modeling and simulation coupled with big data science into translational science, opens up new horizons for investigation,” said Bernard Charlès, President & CEO, Dassault Systèmes.  “This fusion of advanced clinical research and the virtual world is a stepping stone to the future of precision medicine and brings us closer to harmonizing product, nature and life.”

For more information on Dassault Systèmes in the life sciences industry, visit

These contents could be interesting :

Press Contact
Insermrf.mresni@esserp Dassault SystèmesArnaud Malherbe01 61 62 87 73moc.sd3@ebrehlam.duanra